UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000048506 |
|---|---|
| Receipt number | R000055273 |
| Scientific Title | A Multicenter Study to Evaluate the Safety and Effectiveness of SJ-11001-A and SJ-11001-B against Acute Spinal Compression Fracture Due to Primary Osteoporosis |
| Date of disclosure of the study information | 2022/08/01 |
| Last modified on | 2022/07/28 20:24:08 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A Multicenter Study to Evaluate the Safety and Effectiveness of SJ-11001-A and SJ-11001-B against Acute Spinal Compression Fracture Due to Primary Osteoporosis
Acronym
SJ-11001
Scientific Title
A Multicenter Study to Evaluate the Safety and Effectiveness of SJ-11001-A and SJ-11001-B against Acute Spinal Compression Fracture Due to Primary Osteoporosis
Scientific Title:Acronym
SJ-11001
Region
| Japan |
Condition
Condition
Patients with acute spinal compression fracture due to primary osteoporosis
Classification by specialty
| Orthopedics |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the safety and effectiveness of SJ-11001-A and SJ-11001-B in patients with acute spinal compression fracture due to primary osteoporosis.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
1) Restoration rate of vertebral height measured using standing or sitting X-ray images from immediately before to 1 month after procedure
2) Changes in the degree of low back pain based on the NRS pain scores at screening and 7 days after procedure
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Device,equipment |
Interventions/Control_1
Balloon-expanding stent for vertebral body and bone cement
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 40 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
(1) Patients in whom bone density of the lumbar spine (L2-L4) measured by DEXA is less than 80% of YAM or bone atrophy is assessed as Grade 1 or higher by lateral X-ray views and who have painful acute spinal compression fracture in one thoracic or lumbar vertebra: the fifth thoracic vertebra to the fifth lumbar vertebra (T5-L5). As a condition of acute fracture, it has to be confirmed to be fresh fracture by MRI prior to enrollment.
(2) The vertebral height measured at the anterior border part or the central part of the indicated vertebral body has to be decreased to 80% or lower of the mean of the most proximal normal (unfractured) vertebral bodies above and below the indicated vertebra body.
(3) Patients with the number of fractured vertebral body other than the indicated vertebral body is not more than two.
(4) Patients in whom low back pain has not been relieved despite 3 months (12 weeks) of conservative therapy after the onset [including patients in whom low back pain has continued for at least 3 months (12 weeks) with or without treatment]. The following patients who do not respond to conservative therapy are considered eligible even if the onset was within 3 months (12 weeks).
(5) Patients in whom the NRS pain score is 4 or higher for low back pain at screening.
(6) Patients aged 40 years or older from whom written consent can be obtained.
Key exclusion criteria
(1) Patients with any previous spinal surgery.
(2) Patients with spinal fracture that prevents use of the study device.
(3) Patients with pedicle fracture of the indicated vertebral body.
(4) Patients with fracture of the posterior wall of the indicated vertebral body, which has been confirmed by X-ray, CT or MRI.
(5) Patients with pre-existing neurological abnormal findings.
(6) Patients with neurologic symptoms due to spinal cord compression or spinal canal stenosis requiring decompression.
(7) Patients with low back pain that is difficult to resolve due to causes other than the target disease.
(8) Patients with spinal fracture due to vertebral or spinal neoplastic disease or multiple myeloma.
(9) Patients with spinal fracture due to secondary osteoporosis.
(10) Patients in whom anticoagulant therapy cannot be withdrawn.
(11) Patients with systemic infection, local infection of fractured vertebral body, hemorrhagic diathesis.
(12) Patients to whom general anesthesia is inappropriate.
(13) Patients with a previous history of hypersensitivity to bone cement (PMMA) or contrast agents.
(14) Patients in whom a QOL survey is difficult due to dementia or other disorders.
(15) Patients incapable of walking or standing before injury.
(16) Patients in whom MRI is contraindicated.
(17) Patients who are pregnant or plan to become pregnant during the study period.
(18) Patients in whom spinal reconstruction with internal fixation cannot be indicated.
(19) Patients with known hypersensitivity to cobalt-chromium alloy.
Target sample size
87
Research contact person
Name of lead principal investigator
| 1st name | Ryuichi |
| Middle name | |
| Last name | Takemasa |
Organization
Kochi Medical School Hospital
Division name
Department of Orthopaedic Surgery
Zip code
783-0043
Address
185-1 Kohasu, Oko-cho, Nankoku-shi, Kochi, Japan
TEL
088-866-5811
takemasar@yahoo.co.jp
Public contact
Name of contact person
| 1st name | Kumiko |
| Middle name | |
| Last name | Yagi |
Organization
Johnson and Johnson K.K. Medical Company
Division name
Clinical Research
Zip code
101-0065
Address
5-2, Nishi-kanda 3-chome, Chiyoda-ku, Tokyo, Japan
TEL
03-4411-6789
Homepage URL
kyagi1@its.jnj.com
Sponsor or person
Institute
Johnson and Johnson K.K. Medical Company
Institute
Department
Personal name
Funding Source
Organization
Johnson and Johnson K.K. Medical Company
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Kochi Medical School Hospital IRB
Address
185-1 Kohasu, Oko-cho, Nankoku-shi, Kochi, Japan
Tel
088-880-2627
im67@kochi-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2022 | Year | 08 | Month | 01 | Day |
Related information
URL releasing protocol
NA
Publication of results
Unpublished
Result
URL related to results and publications
NA
Number of participants that the trial has enrolled
89
Results
The restoration rates of vertebral height at 1 month after procedure (anterior and central part) were 31.671 +/- 26.462% and 31.835 +/- 24.622%, indicating the clinically significant restoration rate.
The change in NRS pain score was - 4.5 +/- 2.4 at 7 days after operation showing a significant change from screening, indicating the clinically significant decrease.
Results date posted
| 2022 | Year | 07 | Month | 28 | Day |
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Gender: 25 male (28.4%) and 63 female (71.6%).
Age: the mean age was 77.4+/- 8.3 years old.
Participant flow
Agreement was obtained from 97 patients and among them, 89 subjects were enrolled and 8 subjects were not enrolled in the study. Among the enrolled subjects, 88 subjects were operated.
Adverse events
Adverse events of which relationship with malfunction cannot be denied developed in 18 subjects (20.5%, 19 cases) and among them, adverse events of which relationship with malfunction of SJ-11001-A cannot be denied was 17 subjects (19.3%, 18 cases) and adverse events of which relationship with malfunction of SJ-11001-B cannot be denied was 18 subjects (20.5%, 19 cases).
Outcome measures
The restoration rates of vertebral height at 1 month after procedure (anterior and central part) were 31.671+/-26.462% and 31.835+/-24.622%, and corresponding one-sided 95% confidence intervals (lower limits) for mean values were 26.778% and 27.194%. They were exceeded 20%, predefined criterion, indicating the clinically significant restoration rate.
The change in NRS pain score was - 4.5 +/- 2.4 at 7 days after operation showing a significant change from screening. In addition, the one-sided 95% confidence interval (upper limit) for mean value of changes at 7 days after operation was - 4.0, and this was below - 2.0, predefined criterion, indicating the clinically significant decrease.
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2011 | Year | 10 | Month | 28 | Day |
Date of IRB
| 2012 | Year | 03 | Month | 26 | Day |
Anticipated trial start date
| 2012 | Year | 05 | Month | 21 | Day |
Last follow-up date
| 2015 | Year | 03 | Month | 23 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2022 | Year | 07 | Month | 29 | Day |
Last modified on
| 2022 | Year | 07 | Month | 28 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055273
